We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
Read MoreHide Full Article
It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc. (GILD - Free Report) and GSK plc (GSK - Free Report) had a few regulatory updates.
Recap of the Week’s Most Important Stories:
Updates From Gilead Sciences
Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
The designation is based on results from the ES-SCLC cohort of the mid-stage study TROPiCS-03 study. Trodelvy demonstrated promising antitumor activity in both platinum-resistant and platinum-sensitive disease, and the safety profile was consistent with the previous studies. Gilead plans to initiate a phase III study in this patient population.
Concurrently, GILD announced entering a strategic collaboration with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets.
Per the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead. The latter will be responsible for further development and commercialization activities for products resulting from the collaboration if it exercises its option to exclusively license the compounds directed to a target.
In exchange, Terray will receive an upfront payment and be eligible to receive milestone payments associated with achieving preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.
The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended approval of seladelpar. The CHMP adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. A final decision from the European Commission is expected in the first quarter of 2025. The drug is already approved in the United States under the brand name Livdelzi.
Regeneron Pharmaceuticals (REGN - Free Report) announced that the primary endpoint was met in the late-stage QUASAR trial on Eylea HD (aflibercept) injection 8 mg. QUASAR is a global, double-masked, active-controlled phase III study evaluating the efficacy and safety of Eylea HD, compared to Eylea 2 mg, D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion.
Eylea HD demonstrated non-inferior vision gains with an 8-week dosing regimen compared to Eylea injection of 2 mg dosed every 4 weeks. The safety data remains consistent with the known safety profiles of Eylea HD and Eylea.
Regeneron plans to submit a supplementary biologics license application to the FDA in the first quarter of 2025.
ANAB Stock Down on Study Results
AnaptysBio, Inc. (ANAB - Free Report) announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful. Shares of this clinical-stage biotechnology company were down on the results.
The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe atopic dermatitis (AD) or eczema. Patients were randomized to receive for 12 weeks either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W) or 400mg every two weeks (Q2W), or placebo. The primary and secondary endpoints were assessed at week 14. However, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in Eczema Area and Severity Index score (EASI-75), irrespective of the patient type.
ANB032 did not meet any of the secondary endpoints at week 14, including EASI-90, the mean change in baseline EASI or a 4-point reduction in itch severity as measured by the peak Pruritus Numerical Rating Scale (PNRS), compared with placebo.
Due to the disappointing efficacy data from the study, ANAB will discontinue further investment in this asset.
Regulatory and Pipeline Updates From GSK
GSK’s HIV subsidiary, ViiV Healthcare, announced that the CHMP gave a positive opinion recommending marketing authorization to Vocabria (cabotegravir long-acting injections) in combination with Johnson & Johnson’s Rekambys (rilpivirine long-acting injections) for the treatment of HIV-1 infection in virologically suppressed adolescents aged 12 years and above, weighing at least 35 kg.
A decision from the European Commission is expected in the upcoming months.
GSK also announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This population includes patients with mismatch repair proficient/microsatellite stable tumors, who represent 70-75% of patients diagnosed with endometrial cancer with limited treatment options.
GSK announced that the FDA has granted Breakthrough Therapy designation to Jemperli for the treatment of patients with locally advanced mismatch repair deficient or microsatellite instability-high rectal cancer.
Edgewise Stock Up on Study Data
Edgewise Therapeutics (EWTX - Free Report) announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic disorder called Becker Muscular Dystrophy (“BMD”). Shares gained on the news.
The study met its primary endpoint of change from baseline in creatine kinase (CK), a biomarker associated with skeletal muscle damage. Data from the study showed a significant reduction in CK levels in the sevasemten-treated group, with an average decrease of 28% compared to placebo between six and 12 months. The drug was also well-tolerated by study participants.
Treatment with sevasemten showed a trend toward improvement in the key secondary endpoint of the North Star Ambulatory Assessment, a scale commonly used to rate motor function.
Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication.
Image: Bigstock
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc. (GILD - Free Report) and GSK plc (GSK - Free Report) had a few regulatory updates.
Recap of the Week’s Most Important Stories:
Updates From Gilead Sciences
Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
The designation is based on results from the ES-SCLC cohort of the mid-stage study TROPiCS-03 study. Trodelvy demonstrated promising antitumor activity in both platinum-resistant and platinum-sensitive disease, and the safety profile was consistent with the previous studies. Gilead plans to initiate a phase III study in this patient population.
Concurrently, GILD announced entering a strategic collaboration with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets.
Per the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead. The latter will be responsible for further development and commercialization activities for products resulting from the collaboration if it exercises its option to exclusively license the compounds directed to a target.
In exchange, Terray will receive an upfront payment and be eligible to receive milestone payments associated with achieving preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.
The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended approval of seladelpar. The CHMP adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. A final decision from the European Commission is expected in the first quarter of 2025. The drug is already approved in the United States under the brand name Livdelzi.
Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Regeneron’s Study Meets Goals
Regeneron Pharmaceuticals (REGN - Free Report) announced that the primary endpoint was met in the late-stage QUASAR trial on Eylea HD (aflibercept) injection 8 mg. QUASAR is a global, double-masked, active-controlled phase III study evaluating the efficacy and safety of Eylea HD, compared to Eylea 2 mg, D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion.
Eylea HD demonstrated non-inferior vision gains with an 8-week dosing regimen compared to Eylea injection of 2 mg dosed every 4 weeks. The safety data remains consistent with the known safety profiles of Eylea HD and Eylea.
Regeneron plans to submit a supplementary biologics license application to the FDA in the first quarter of 2025.
ANAB Stock Down on Study Results
AnaptysBio, Inc. (ANAB - Free Report) announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful. Shares of this clinical-stage biotechnology company were down on the results.
The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe atopic dermatitis (AD) or eczema. Patients were randomized to receive for 12 weeks either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W) or 400mg every two weeks (Q2W), or placebo. The primary and secondary endpoints were assessed at week 14. However, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in Eczema Area and Severity Index score (EASI-75), irrespective of the patient type.
ANB032 did not meet any of the secondary endpoints at week 14, including EASI-90, the mean change in baseline EASI or a 4-point reduction in itch severity as measured by the peak Pruritus Numerical Rating Scale (PNRS), compared with placebo.
Due to the disappointing efficacy data from the study, ANAB will discontinue further investment in this asset.
Regulatory and Pipeline Updates From GSK
GSK’s HIV subsidiary, ViiV Healthcare, announced that the CHMP gave a positive opinion recommending marketing authorization to Vocabria (cabotegravir long-acting injections) in combination with Johnson & Johnson’s Rekambys (rilpivirine long-acting injections) for the treatment of HIV-1 infection in virologically suppressed adolescents aged 12 years and above, weighing at least 35 kg.
A decision from the European Commission is expected in the upcoming months.
GSK also announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This population includes patients with mismatch repair proficient/microsatellite stable tumors, who represent 70-75% of patients diagnosed with endometrial cancer with limited treatment options.
GSK announced that the FDA has granted Breakthrough Therapy designation to Jemperli for the treatment of patients with locally advanced mismatch repair deficient or microsatellite instability-high rectal cancer.
Edgewise Stock Up on Study Data
Edgewise Therapeutics (EWTX - Free Report) announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic disorder called Becker Muscular Dystrophy (“BMD”). Shares gained on the news.
The study met its primary endpoint of change from baseline in creatine kinase (CK), a biomarker associated with skeletal muscle damage. Data from the study showed a significant reduction in CK levels in the sevasemten-treated group, with an average decrease of 28% compared to placebo between six and 12 months. The drug was also well-tolerated by study participants.
Treatment with sevasemten showed a trend toward improvement in the key secondary endpoint of the North Star Ambulatory Assessment, a scale commonly used to rate motor function.
Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication.
Performance
The Nasdaq Biotechnology Index has declined 1.98% in the past five trading sessions and Regeneron’s shares have lost 4.95%. In the past six months, shares of MRNA have plunged 70.44%. (See the last biotech stock roundup here: Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More)
Image Source: Zacks Investment Research
What's Next in Biotech?
Stay tuned for more pipeline updates.